Michael Bader Selected Research

Apolipoproteins E (ApoE)

1/2022	Role of Gpnmb in atherosclerosis of female mice.
1/2021	(Pro)renin Receptor Inhibition Reduces Plasma Cholesterol and Triglycerides but Does Not Attenuate Atherosclerosis in Atherosclerotic Mice.
1/2020	CYP17A1 deficient XY mice display susceptibility to atherosclerosis, altered lipidomic profile and atypical sex development.
12/2016	Role of the receptor Mas in macrophage-mediated inflammation in vivo.
12/2013	Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice.
10/2009	Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Bader Research Topics

Disease

43	Inflammation (Inflammations) 11/2023 - 12/2002
36	Hypertension (High Blood Pressure) 01/2023 - 06/2002
19	Cardiomegaly (Heart Hypertrophy) 12/2022 - 11/2002
17	Insulin Resistance 01/2024 - 02/2008
17	Fibrosis (Cirrhosis) 01/2024 - 08/2002
15	Body Weight (Weight, Body) 04/2024 - 03/2005
15	Obesity 01/2023 - 06/2008
13	Hypertrophy 01/2024 - 09/2002
11	Ischemia 01/2023 - 01/2002
11	Neoplasms (Cancer) 01/2022 - 01/2002
9	Pain (Aches) 11/2023 - 12/2002
9	Myocardial Infarction 01/2017 - 04/2005
8	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 01/2010
7	Weight Gain 12/2023 - 06/2008
7	Stroke (Strokes) 01/2023 - 02/2002
7	Type 2 Diabetes Mellitus (MODY) 01/2022 - 02/2009
7	Infarction (Infarctions) 01/2011 - 02/2002
6	Pulmonary Arterial Hypertension 05/2024 - 01/2007
6	Carcinoid Tumor (Carcinoid) 01/2024 - 06/2002
6	Hyperalgesia 01/2016 - 12/2002
5	Infections 03/2024 - 01/2003
5	Pre-Eclampsia (Preeclampsia) 01/2023 - 09/2014
5	Atrophy 12/2022 - 04/2016
5	Atherosclerosis 01/2021 - 10/2009
5	Heart Failure 01/2020 - 10/2004
5	Edema (Dropsy) 11/2015 - 01/2003
4	Mental Disorders (Mental Disorder) 02/2023 - 11/2003
4	AIDS-Related Complex (ARC) 04/2022 - 03/2006
4	Melanoma (Melanoma, Malignant) 10/2021 - 04/2005
4	Proteinuria 01/2021 - 01/2004
4	Neuralgia (Stump Neuralgia) 01/2020 - 03/2005
4	Spinal Cord Injuries (Spinal Cord Injury) 01/2020 - 01/2018
4	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019 - 04/2006
4	Diabetes Mellitus 01/2019 - 12/2004
4	Necrosis 01/2017 - 01/2002
4	Wounds and Injuries (Trauma) 05/2016 - 02/2004
4	Fatty Liver 12/2013 - 06/2003
4	Heart Diseases (Heart Disease) 02/2013 - 01/2003
4	Vascular Remodeling 08/2011 - 09/2002
4	Hypoxia (Hypoxemia) 06/2008 - 02/2002
3	Cognitive Dysfunction 05/2024 - 11/2016
3	Albuminuria 01/2023 - 04/2006
3	Thrombosis (Thrombus) 01/2022 - 12/2003
3	Pneumonia (Pneumonitis) 01/2021 - 12/2008
3	Hypertensive Nephropathy 11/2020 - 02/2014
3	Non-alcoholic Fatty Liver Disease 05/2020 - 08/2007
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 02/2008
3	Glucose Intolerance 01/2020 - 02/2008

Drug/Important Bio-Agent (IBA)

49	KininsIBA 04/2024 - 01/2002
28	Serotonin (5 Hydroxytryptamine)IBA 05/2024 - 06/2002
25	Angiotensin IIIBA 01/2024 - 02/2002
23	ReninIBA 01/2024 - 02/2002
21	BradykininIBA 08/2023 - 08/2002
19	AngiotensinsIBA 01/2023 - 01/2004
19	angiotensin I (1-7)IBA 01/2023 - 05/2002
18	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2002
15	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 02/2008
13	AngiotensinogenIBA 01/2024 - 02/2002
13	Peptides (Polypeptides)IBA 11/2023 - 11/2002
12	Messenger RNA (mRNA)IBA 01/2023 - 02/2002
12	LeptinIBA 01/2020 - 02/2008
9	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2024 - 01/2003
9	CytokinesIBA 01/2023 - 04/2004
8	Tryptophan HydroxylaseIBA 05/2024 - 06/2002
8	EnzymesIBA 01/2024 - 02/2002
8	LipidsIBA 10/2021 - 06/2003
8	Insulin (Novolin)FDA Link 01/2021 - 02/2008
8	LipopolysaccharidesIBA 12/2020 - 01/2003
8	2,5-dichloro-4-bromophenol (B 2)IBA 10/2011 - 12/2002
7	Streptozocin (Streptozotocin)FDA Link 01/2019 - 06/2002
7	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2017 - 06/2003
7	Bradykinin Receptors (Bradykinin Receptor)IBA 09/2012 - 11/2006
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2022 - 08/2002
6	Apolipoproteins E (ApoE)IBA 01/2022 - 10/2009
5	SaltsIBA 01/2024 - 02/2002
5	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2023 - 06/2008
5	Kallikreins (Kallikrein)IBA 01/2022 - 09/2002
5	salicylhydroxamic acid (SHAM)IBA 01/2020 - 04/2005
5	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2020 - 02/2002
5	CollagenIBA 12/2019 - 11/2006
5	AldosteroneIBA 09/2014 - 03/2005
4	alamandineIBA 01/2023 - 04/2013
4	AcidsIBA 07/2018 - 06/2003
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 03/2008
4	icatibantIBA 03/2013 - 05/2002
3	NeuropeptidesIBA 01/2024 - 05/2008
3	Type 3 Cyclic Nucleotide PhosphodiesterasesIBA 01/2023 - 01/2020
3	Norepinephrine (Noradrenaline)FDA LinkGeneric 09/2022 - 01/2008
3	compound 21IBA 01/2022 - 03/2010
3	Blood Glucose (Blood Sugar)IBA 12/2021 - 03/2014
3	AlbuminsIBA 12/2021 - 11/2002
3	Prorenin ReceptorIBA 01/2021 - 12/2011
3	Insulin ReceptorIBA 01/2021 - 01/2017
3	CholesterolIBA 01/2021 - 10/2009
3	Angiotensin-Converting Enzyme 2IBA 12/2020 - 11/2008
3	CreatinineIBA 11/2020 - 01/2004
3	FR 173657IBA 01/2020 - 01/2009
3	Karyopherins (Importin)IBA 01/2020 - 01/2018

Therapy/Procedure

12	Therapeutics 01/2023 - 01/2011
3	Oral Administration 04/2024 - 03/2014